Loading...
Caritas Healthcare Private Limited — Rivaroxaban Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Rivaroxaban · $1.1M export value · DGFT Verified
Caritas Healthcare Private Limited is the #4 Indian exporter of Rivaroxaban with $1.1M in export value and 22 verified shipments. Caritas Healthcare Private Limited holds a 2.1% market share in Rivaroxaban exports across 1 countries. The company exports 9 pharmaceutical products worth $7.2M across 6 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $11.4M | 229 | 31.1% |
| MALTA | $5.0M | 267 | 13.7% |
| CANADA | $3.2M | 77 | 8.6% |
| BRAZIL | $2.6M | 62 | 7.2% |
| AUSTRALIA | $2.4M | 57 | 6.6% |
| UNITED KINGDOM | $2.3M | 83 | 6.2% |
| ECUADOR | $1.5M | 30 | 4.1% |
| SOUTH AFRICA | $1.4M | 51 | 3.9% |
| FRANCE | $1.3M | 49 | 3.5% |
| CHILE | $1.2M | 88 | 3.4% |
India exports Rivaroxaban to 115 countries. The top destination is NETHERLANDS (31.1%), followed by MALTA and CANADA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN IRELAND C/O ALLOGA RDC, | NETHERLANDS | $4.2M | 83 |
| PHARMADOX HEALTHCARE LTD | MALTA | $3.9M | 194 |
| APOTEX INC | CANADA | $1.3M | 27 |
| PHARMADOX HEALTHCARE LIMITED | MALTA | $1.1M | 50 |
| MYLAN IRELAND C/O ALLOGA RDC,. | NETHERLANDS |
India exported $36.7M worth of Rivaroxaban through 5,361 shipments from 221 suppliers to 115 countries, serving 497 buyers globally. Caritas Healthcare Private Limited contributes $1.1M to this total, accounting for 2.1% of India's Rivaroxaban exports.
Caritas Healthcare Private Limited's average Rivaroxaban shipment value is $50.0K per consignment, based on 22 shipments totaling $1.1M.
Caritas Healthcare Private Limited ranks #4 among 221 Indian Rivaroxaban exporters with a 2.1% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($12.8M), DR.REDDY'S LABORATORIES LTD ($5.2M), ZENTIVA PRIVATE LIMITED ($3.2M). Caritas Healthcare Private Limited processed 22 shipments to 1 destination countries.
What Caritas Healthcare Private Limited must comply with to export Rivaroxaban to its top destination countries
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | ALEMBIC PHARMACEUTICALS LIMITED | $1.3M | 38 | 7 | $33.5K |
| 11 | LUPIN LIMITED | $1.2M | 28 | 3 | $44.2K |
| 4 | CARITAS HEALTHCARE PRIVATE LIMITED ★ | $1.1M | 22 | 1 | $50.0K |
| 12 | UNISON PHARMACEUTICALS PRIVATE LIMITED | $1.1M |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,144 | 21.3% |
| DELHI AIR CARGO ACC (INDEL4) | 985 | 18.4% |
| DELHI AIR | 659 | 12.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 635 | 11.8% |
| Bombay Air | 197 | 3.7% |
| NHAVA SHEVA SEA (INNSA1) | 164 | 3.1% |
| Delhi Air | 133 | 2.5% |
| HYDERABAD AIR | 110 | 2.1% |
Caritas Healthcare Private Limited also exports these cardiovascular products. Each links to the detailed product page.
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Caritas Healthcare. The Israel-Iran conflict has disrupted Middle East trade routes, leading to increased shipping costs and logistical complexities. Reports indicate that maritime carriers have suspended bookings for sailings into the Persian Gulf, and vessels are being diverted around the Cape of Good Hope, extending transit times and escalating freight charges. (pharmaceuticalcommerce.com) These disruptions necessitate strategic adjustments in shipment schedules and inventory management to mitigate potential losses.
Conversely, the India–European Union Free Trade Agreement, concluded on January 27, 2026, is poised to eliminate tariffs on pharmaceuticals, enhancing market access for Indian exporters. (en.wikipedia.org) This development offers Caritas Healthcare an opportunity to strengthen its presence in the European market, capitalizing on reduced trade barriers and increased competitiveness.
India's pharmaceutical industry has made significant strides in regulatory compliance, with the country surpassing the United States in the number of FDA-registered generic manufacturing sites as of 2024. (business-standard.com) This achievement reflects a concerted effort to adhere to stringent international quality standards. For Caritas Healthcare, maintaining compliance with FDA, WHO GMP, and EU regulations is imperative to sustain and expand its export operations. Continuous investment in quality assurance and regulatory adherence will be crucial in navigating the evolving global pharmaceutical landscape.
Caritas Healthcare Private Limited exports 9 products worth $7.2M. Beyond Rivaroxaban, top products include Tacrolimus, Carvedilol, Methylprednisolone, Amphotericin, Chloroquine. View the complete Caritas Healthcare Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Rivaroxaban — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Caritas Healthcare Private Limited's Rivaroxaban exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Caritas Healthcare Private Limited
Full Company Profile →
9 products · $7.2M total trade · 6 categories
| $911.1K |
| 46 |
| BIOLAB FARMA GENERICO | BRAZIL | $750.0K | 15 |
| GMP MANUFACTURING LTD | UNITED KINGDOM | $600.0K | 12 |
| TO THE PURCHASE MANAGER | ECUADOR | $450.0K | 9 |
| DEPO PACK SNC | ITALY | $250.0K | 5 |
| HEALTH CARE AGENCY, SEYCHELLES | SEYCHELLES | $150.0K | 3 |
India's Rivaroxaban is purchased by 497 buyers worldwide. The top buyer is MYLAN IRELAND C/O ALLOGA RDC, (NETHERLANDS), followed by PHARMADOX HEALTHCARE LTD and APOTEX INC.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 41 |
| 6 |
| $26.7K |
| 14 | MILAN LABORATORIES (INDIA) PRIVATE LIMITED | $853.4K | 31 | 1 | $27.5K |
Caritas Healthcare Private Limited ranks #4 among 221 Indian Rivaroxaban exporters. Average shipment value of $50.0K compared to the market average of $166.0K. The closest competitors by value are ALEMBIC PHARMACEUTICALS LIMITED and LUPIN LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 115+ countries, 497+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Caritas Healthcare Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rivaroxaban. For current shipment-level data, contact TransData Nexus.